Welcome to YHEC’s publication hub

Our latest research, all in one place. Browse our collection of journal articles, reports and conference proceedings to see how we’re contributing to HEOR research. Remember to: 

  • Filter by service, therapeutic area, or geography to narrow your results.
  • Search directly for keywords or specific titles to find what you need instantly.
Peer-reviewed publication

Estimation of the Health Economic Benefit of Widening Pulmonary Rehabilitation Uptake and Completion

YHEC authors: James Mahon, Nick Hex
Publication date: December 2024
Journal: Chronic Respiratory Disease

Abstract

OBJECTIVES: Increasing uptake and completion of Pulmonary Rehabilitation in people with COPD has the potential to deliver health benefit and reduce health inequalities. We have quantified the cost-effectiveness of enhancing PR access and completion by reviewing the cost-effectiveness literature for PR in COPD.

METHODS: A literature review identified studies that provided cost-effectiveness evidence for PR compared to no PR. The key metrics of interest were healthcare resource use and cost savings, and quality adjusted life year (QALY) gains. Healthcare resource use data were valued using the UK NHS National Tariff 2022/23. From the literature search we identified the QALY gain resulting from completion of PR. The value of the QALY gain resulting from PR completion was calculated using the standard willingness-to-pay threshold of £20,000 considered by the UK National Institute for Health and care Excellence (NICE).

RESULTS: We estimated a QALY gain resulting from completion of PR of 0.065 and value of the QALY gain was therefore calculated to be £1300 per person completing PR. We estimated the 12 month reduction in hospitalisation following completion of PR to be 8.2% giving a total cost reduction per patient of £245. We therefore calculated that up to £1545 could be spent per person with COPD to deliver PR cost-effectively.

CONCLUSION: Our analysis provides commissioners with the information they need to make informed decisions about planning and provision of PR. The data allows estimation of additional resources that could be deployed in addressing inequitable access to PR among disadvantaged and underserved populations whilst retaining cost effectiveness of the intervention.

Conference proceeding

A Call for Standardisation: Navigating the Inconsistency in European HTA Pharmacoeconomic Guideline Reporting

YHEC authors: Damian Lewis, Andria Joseph, Stuart Mealing
Publication date: November 2024
Conference: ISPOR EU, Barcelona
Type of conference proceeding: Poster

Abstract

OBJECTIVES: Health technology assessment (HTA) processes are applied throughout Europe to evaluate the comparative clinical and economic value of a novel intervention to inform resource allocation decision-making. Various economic evaluation frameworks are employed in European HTA submissions, including - predominantly - cost-effectiveness and cost-utility analyses and this research explores the clarity and standardisation (or lack thereof) of these evaluations in a European context.

METHODS: A pragmatic literature review was performed on all relevant European HTAs which covered the United Kingdom, Scandinavia, Western Europe, Central and Southern Europe. It is clear there is substantial amount of information generated by economic evaluations and systematic literature reviews, checklists such as CHEERs and PRISMA which are available to inform the standards and minimum amount of information for reporting, ensuring consistency and transparency. However, similar consideration is not given to the reporting of pharmacoeconomic guidelines, and between-country variation in the format, content and standard of reporting limits the comparability and transferability between guidelines.

RESULTS: Guidelines for agencies such as the TLV, SUKL and AIFA are also not universally available in additional languages. EU HTA Regulation, published in January 2022, aims to standardise clinical assessment of pharmaceutical interventions to enable a central assessment across the 27 EU markets. Joint Clinical Assessment is reportedly beginning implementation in January 2025, signalling increased cross-country collaboration in HTA. There is an opportunity for further standardisation in evidentiary requirement reporting.

CONCLUSIONS: By providing a standardised, validated template for reporting pharmacoeconomic guideline requirements would aid companies when planning clinical trials, ensuring the necessary patient outcomes are collected. Clearer reporting surrounding preferred methods, evidence sources (e.g. value sets, population norm data) may contribute to higher evidence standards. Consensus across EU HTA agencies may also inform standards for less established agencies, such as AIFA, aiding development of HTA procedures in their respective regions.

Conference proceeding

A Taxonomy of the Impact of Precision Medicine in HTA

YHEC authors: Matthew Taylor
Publication date: November 2024
Conference: ISPOR EU, Barcelona
Type of conference proceeding: Poster

Abstract

OBJECTIVES: Healthcare systems are increasingly using 'precision medicine' to ensure that patients receive the most appropriate treatment. Whilst the benefits of precision medicine are widely discussed, there is less discussion around the circumstances where precision medicine is most likely to reap benefits, and even less discussion around the potential downsides of precision medicine. This study aims to address these points.

METHODS: A hypothetical case study was developed that with two available treatments: T1 (with an effectiveness rate of 90%) and T2 (effectiveness = 60%). Different scenarios are run, where the individual patients who would benefit from T2 are (i) entirely 'within' the 90% that would also benefit from T1, (ii) covering the 10% who would not benefit from T1 but also including some would benefit from T1, and (iii) an 'overlapping' case in-between. For each scenario, two options were assessed: 'With precision medicine' (i.e. the decision maker can identify which patients will benefit from each treatment) and 'no precision medicine'.

RESULTS: In all scenarios, total population health increased when precision medicine would be applied. Costs were reduced in all scenarios, although this did not include the cost of implementing the precision medicine approach itself. Decision making was shown to be more complex, because precision medicine would introduce multiple layers of decisions. Data requirements were greatly increased with precision medicine, and decision uncertainty was also greater (due to smaller sample sizes within smaller subgroups). In a health system that uses value-based pricing, value was shown not to increase, since the price of treatments would likely increase in line with the improved effectiveness due to precision medicine methods.

CONCLUSIONS: In the case study presented, precision medicine methods delivered increase population health, but the value for money varied considerably between scenarios. Better understanding of disease areas in which precision medicine will benefit patients is essential.

Conference proceeding

Advancing Real-World Evidence and Health Technology Assessment for Medical Devices and Diagnostics

YHEC authors: Lavinia Ferrante di Ruffano
Publication date: November 2024
Conference: ISPOR EU, Barcelona
Type of conference proceeding: Panel

Abstract

Health technology assessment (HTA) evaluates the benefits of medical technologies and helps determine the value of a diagnostic or medical intervention and whether it should be made available in a health system. Real World Evidence (RWE) provides insights on how technologies are used and perform in a real world setting and is becoming increasingly important for reimbursement and regulatory decision making.
HTA submissions typically use generic frameworks for assessing medical innovations, which are not specific for diagnostics or medical devices, and may hinder how their value is measured and evaluated. Additionally, these frameworks may not include RWE, which is important to enable a complete evaluation of evidence, particularly for medical devices.

This forum aims to highlight opportunities for improvements to HTA frameworks to more fully capture the value of diagnostics and medical devices. Case studies will be used to illustrate uses of RWE and the importance of including a tailored evidence evaluation framework for diagnostics and medical devices. The forum will also include a state of the art discussion on the methods to evaluate diagnostic tests (Dr. Lavinia Ferrante), a presentation on the current challenges experienced by HTAs for the assessment on these technologies (Mr. David Tamblyn), and a discussion with two medical device companies (representatives: Lindsay Bockstedt and Chiara Capobianco) presenting their approaches in using RWE, and sharing how evidence standards may evolve as RWE becomes more widely accepted. The panel will conclude with questions from the moderator and the audience.

Conference proceeding

Aligning Health Technology Assessment With Healthcare Net Zero Targets: A Parallel Evaluation of Single Use Versus Reusable Devices

YHEC authors: Melissa Pegg
Publication date: November 2024
Conference: ISPOR EU, Barcelona
Type of conference proceeding: Poster

Abstract

OBJECTIVES: Healthcare's supply chain contributes 62% of the 25 million tonnes of CO2e emissions generated by the UK National Health Services per annum. Changing from single use equipment to reusable equivalent can reduce CO2e up to 56%. The SHTG recognized the need to evaluate the environmental credentials of single use equipment through a parallel assessment alongside a health economic analysis. This novel research is the first UK parallel assessment published the Scottish Health Technologies Group (SHTG). An innovative hybrid approach utilized multidisciplinary methods to overcome data challenges. The findings of the report are in line with research and provides important methods for HTA sustainability globally.

METHODS: Applying environmental management frameworks, a carbon footprint of single use rhinolaryngoscopes was compared with a reusable equivalent. Data collection techniques included questionnaires, interviews and the use of guidance for technological representativeness were used to quantify national GHG emissions and waste volumes. The technologies were categorized using thresholds based on the functional unit, to strengthen support for the HTA decision making process. Sensitivity analyses were performed.

RESULTS: The carbon emissions of a single use flexible rhinolaryngoscope compared to its reusable equivalent was 6.03kgCO2e and 3.26kgCO2e respectively. Data extrapolation reveals the annual environmental impact of this technology, throughout NHS Scotland, to be 13,652kgCO2e and 7,381kgCO2e, for the single use and reusable devices, respectively. Raw material acquisition, the use of personal protective equipment and transportation were carbon hotspots. Use of the single use devices generates 12.58 tonnes of waste per year further burdening healthcare resources. This pilot study recommends the use a reusable equivalent in this setting.

CONCLUSIONS: Aligned with NHS net zero targets, these findings confirm the need to perform a parallel environmental assessment of technologies alongside a health economic analysis. Data constraints can be overcome using hybrid methodologies. This work support policy development in HTA sustainability framework development.

Peer-reviewed publication

An Economic Evaluation of First-Line Cryoballoon Ablation versus Antiarrhythmic Drug Therapy for the Treatment of Paroxysmal Atrial Fibrillation from a German Healthcare Payer Perspective

YHEC authors: Lucy Hillcoat, Joe Moss, Stuart Mealing, Tom Bromilow, Damian Lewis
Publication date: November 2024
Journal: BMC Health Services Research

Abstract

BACKGROUND: Three recent randomized controlled trials demonstrated that, in patients with symptomatic paroxysmal atrial fibrillation (PAF), first-line pulmonary vein isolation with cryoballoon catheter ablation reduces atrial arrhythmia recurrence compared to initial antiarrhythmic drug (AAD) therapy. This study aimed to evaluate the cost-effectiveness of first-line cryoablation compared to first-line AADs from a German healthcare payer perspective.

METHODS: Individual patient-level data from 703 participants with untreated PAF enrolled into three randomized clinical trials (Cryo-FIRST, STOP AF First and EARLY-AF) were used to derive parameters for the cost-effectiveness model (CEM).

The CEM structure consisted of a hybrid decision tree and Markov model. The decision tree (one-year time horizon) informed initial health state allocation in the first cycle of the Markov model (40-year time horizon; three-month cycle length). Health benefits were expressed in quality-adjusted life years (QALYs). Cost inputs were sourced from German diagnosis-related groups and the Institute for the Hospital Remuneration System (InEK). Costs and benefits were discounted at 3% per annum.

RESULTS: Cryoablation was cost-effective, incurring ~ €200 per patient while offering an increase in QALYs (~ 0.18) over a lifetime. This produced an average incremental cost-effectiveness ratio of ~ €1,000 per QALY gained. Individuals were expected to receive ~ 1.2 ablations over a lifetime, regardless of initial treatment. However, those initially treated with cryoablation as opposed to AADs experience 0.9 fewer re-ablations and a 45% reduction in time spent in AF health states.

CONCLUSION: Initial rhythm control with cryoballoon ablation in symptomatic PAF is a cost-effective treatment option in a German healthcare setting.

Conference proceeding

An Economic Model to Assess the Costs and Benefits of Workplace Mental Wellbeing Interventions: A Flexible Tool for Employers and Decision Makers

YHEC authors: Matthew Taylor, Stuart Mealing, Emily Gregg, Karina Watts
Publication date: November 2024
Conference: ISPOR EU, Barcelona
Type of conference proceeding: Poster

Abstract

OBJECTIVES: Poor mental wellbeing is one of the leading causes of long-term sickness absence from work despite conditions, such as stress and anxiety, being treatable and often preventable. The aim of this analysis was to conduct economic modelling and provide data on costs and benefits to employers who are considering implementing a workplace intervention to improve wellbeing. Additionally, the analysis was used to assess any changes in employee outcomes (e.g. productivity and staff turnover).

METHODS: A cost-consequence model with a one-year time horizon was developed to assess the impact of workplace mental wellbeing interventions. Because all workplaces are different, it is not useful to present one single base case. Instead, the model generates a series of hypothetical case studies, with varying levels of absenteeism, presenteeism and staff turnover, as well as different levels of productivity and staff replacement costs. Several mental wellbeing interventions were compared with 'no intervention' (current practice) to calculate the total incremental costs and incremental cost per employee.

RESULTS: In the hypothetical case study with 50 employees and an intervention cost of £100, the intervention had a net cost saving of £3,395 per employee. Savings were due to reductions in absenteeism and presenteeism. Sensitivity analysis assessed the impact of varying each input, to reflect that the inputs will vary substantially for each individual organization and setting. The intervention is more likely to be cost saving when the baseline level of absenteeism and staff turnover are high, and the level of presenteeism and intervention cost are low.

CONCLUSIONS: Mental wellbeing interventions may influence a range of outcomes but outcomes demonstrating a mental wellbeing benefit to employees may be challenging to translate into monetary value. The model can be used by decision makers and employers to understand the potential economic and wellbeing implications of implementing a mental wellbeing intervention in the workplace.

1 … 10 11 12 13 14 … 83